Contrast Media & Molecular Imaging

Review Article

PET/CT Evaluation of the Effect of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of T-Cell Lymphoblastic Lymphoma

Table 2

Statistics of interim ¹⁸F-FDG PET/CT prediction study results.


References	Research results	Research conclusion

Reference [29]	¹⁸F-FDG PET/CT facilitated complete recovery and transition to HCT in two patients.	FDG-PET/CT had a new role in the diagnostic and surveillance pathways of complex infections in high-risk immunocompromised patients.

Reference [30]	There was a significant difference in ¹⁸F-FLT intensity between pre-HSCT myeloablative infusion and subclinical stellate recovery (p = 0.00031).	¹⁸F-FLT allowed quantification and tracking of human subclinical bone marrow regeneration and reveals new insights into the biology of stellate cell recovery after HSCT.

Reference [31]	The sensitivity of FLT-PET/CT was lower than that of FDG-PET/CT	The uptake of 18F-FDG in tumor tissue was higher than that of ¹⁸F-FLT

Reference [32]	ASCT ¹⁸F-FDG positivity after PET-CT was associated with lower PFS and OS; PET-CT outcome was the only independent factor associated with OS (p = 0.028); PET within 3–6 months after ASCT-In patients with CT scan, the PFS and OS prognosis were better in the PET-CT negative group	¹⁸F-FDG PET/CT technology had high application value in predicting PFS and OS of patients after stem cell transplantation (especially the 3–6 months window period)

Reference [33]	PET/CT after HSCT (post-PET) was associated with PFS (P = 0.030). However, none of the assessed factors predicted OS.	This meant that PET may help guide subsequent clinical treatment decisions.

Reference [34]	PET results were associated with 3-year PFS [HR = 4.391, P = 0.001; HR = 7.607, ] and OS (HR = 4.792, P = 0.008; HR = 26.138, ).	PET results were a useful prognostic factor in patients undergoing HSCT.